Neurocrine Biosciences (NBIX) Total Current Liabilities (2010 - 2026)

Neurocrine Biosciences (NBIX) has reported Total Current Liabilities for 17 consecutive years, with $874.5 million the latest figure, recorded in Q2 2026.

• For the quarter ending Q2 2026, Total Current Liabilities rose 60.08% year-over-year to $874.5 million; the trailing twelve-month figure through Jun 2026 stood at $874.5 million (up 60.08% YoY), and the FY2025 full-year result was $743.4 million, up 46.43% from the prior year.
• Total Current Liabilities advanced to $874.5 million in Q2 2026 per NBIX's latest filing, from $831.7 million in the prior quarter.
• Across five years, Total Current Liabilities topped out at $874.5 million in Q2 2026 and bottomed at $253.5 million in Q1 2022.
• Historically, Total Current Liabilities has averaged $559.5 million across 5 years, with a median of $542.0 million in 2022.
• The sharpest annual moves came in 2022 and 2024: Total Current Liabilities soared 118.76% in 2022, then tumbled 37.87% in 2024.
• Over 5 years, Total Current Liabilities stood at $537.7 million in 2022, then gained by 21.78% to $654.8 million in 2023, then decreased by 22.46% to $507.7 million in 2024, then jumped by 46.43% to $743.4 million in 2025, then increased by 17.64% to $874.5 million in 2026.
• According to Business Quant data, Total Current Liabilities over the past three periods registered $874.5 million, $831.7 million, and $743.4 million for Q2 2026, Q1 2026, and Q4 2025 respectively.